Home・Stock List・CareDx Inc

CareDx Inc

Closed

SectorHealthcare

46.97 0.09

Buy Sell

Overview

Share price change

24h

Current

Min

46.42

Max

47.53

Key metrics
By Trading Economics
Income	108M 111M
Sales	14M 132M
P/E Sector Avg	22.522 57.002
EPS	0.17
Profit margin	83.848
Employees	761
EBITDA	-3.8M 4.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+1.1% upside

Dividends
By Acuity
Next Earnings	3 Nov 2026

Market Stats
By TradingEconomics
Market Cap	557M 2.4B
Previous open	46.88
Previous close	46.97

News Sentiment

By Acuity

50%

135 / 340 Healthcare

CareDx Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 Aug 2026, 23:41 UTC

CareDx Inc shares advanced in after-market trading, reflecting notable gains since Tuesday's close. The stock remains well above its 20-day moving average.

10 Aug 2026, 23:46 UTC

CareDx Inc shares are higher in after-market hours, trading significantly above their 20-day moving average and near the upper end of their one-month range.

7 Aug 2026, 20:06 UTC

CareDx Inc shares are higher today, recovering from an early dip. The stock has gained significantly since Thursday amid a decline in Treasury yields.

5 Aug 2026, 19:46 UTC

Shares of CareDx Inc. are lower today amid unusual volatility, reflecting a broader market sentiment influenced by disappointing employment data from ADP.

4 Aug 2026, 21:36 UTC

CareDx Inc shares are higher in after-market trading, reflecting a broader U.S. stock rally amid declining crude oil prices easing inflation concerns.

3 Aug 2026, 20:02 UTC

News

CareDx Inc shares rise following a rating upgrade to Buy from Craig-Hallum and a new price target of $64, up from $35.

31 Jul 2026, 23:06 UTC

News

CareDx shares are lower in after-market hours despite a 52% revenue increase to $132 million and raised full-year guidance to $490 million-$500 million.

30 Jul 2026, 23:41 UTC

News

CareDx Inc reported second-quarter revenue of $132 million, exceeding estimates. Following strong results and raised guidance, shares are higher in after-market trading.

29 Jul 2026, 19:56 UTC

CareDx Inc shares are lower, continuing a six-session decline amid rising crude oil prices and inflation concerns affecting broader market sentiment.

27 Jul 2026, 19:16 UTC

News

CareDx Inc is trading lower today, reflecting broader market trends amid declining oil prices and easing geopolitical tensions ahead of the Federal Reserve meeting.

22 Jul 2026, 19:16 UTC

CareDx Inc shares are lower today with no specific news identified. Broader market sentiment is affected by rising crude oil prices amid geopolitical tensions.

20 Jul 2026, 18:53 UTC

News

CareDx shares are lower as Director Valantine Hannah sold 28,779 shares at prices between $36.14 and $36.55, raising investor concerns.

Peer Comparison

Price change

CareDx Inc Forecast

Price Target

By TipRanks

1.1% upside

12 Months Forecast

Average 47.75 USD 1.1%

High 64 USD

Low 21 USD

Based on 5 Wall Street analysts offering 12 month price targets forCareDx Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to CareDx Inc - Dist in the past 3 months.

Sentiment

By Acuity

135 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.